Considering that a considerable proportion of NSCLC patients had EGFR/KRAS mutations, it could be expected that ALK rearrangements will be more common among patients with EGFR/KRAS wild-type mutations, as reported by some observations [60], [62], [77]. Here, KRAS is linked to non-small cell lung carcinoma.